

## FORM 11

### NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: **BioMark Diagnostics Inc.** (the "Issuer").

Trading Symbol: **BUX**

Date: **April 18, 2024**

**1. New Options Granted:**

Date of Grant: April 18, 2024

<b>Name of Optionee</b>	<b>Position (Director/ Officer/ Employee/ Consultant/ Management Company)</b>	<b>Insider Yes or No?</b>	<b>No. of Optioned Shares</b>	<b>Exercise Price</b>	<b>Expiry Date</b>	<b>No. of Options Granted in Past 12 Months</b>
Jean-Francois Haince	Consultant	No	500,000	0.45	April 18, 2027	No
Alfred R. Berkeley III	Advisor	No	500,000	0.45	April 18, 2027	No
Richard William Robertson	Advisor	No	425,000	0.45	April 18, 2027	No
Pluralite Inc.	Consultant	No	420,000	0.45	April 18, 2027	No
Kevin J. Cosgriff	Advisor	No	400,000	0.45	April 18, 2027	No
Randolph Ford	Advisor	No	200,000	0.45	April 18, 2027	No
Theresa Peterson	Advisor	No	200,000	0.45	April 18, 2027	No
Barbara W. Cosgriff	Advisor	No	170,000	0.45	April 18, 2027	No
Jean Manasse Theasene	Advisor	No	100,000	0.45	April 18, 2027	No
Paramjit Singh Tappia	Scientific Advisor	No	30,000	0.45	April 18, 2027	No
Tomas Raycove	Consultant	No	30,000	0.45	April 18, 2027	No
Chloe Gaudreault- Desrosiers	Employee	No	50,000	0.45	April 18, 2027	No
Stephanie Girardeau	Employee	No	50,000	0.45	April 18, 2027	No
Andriamahay Jonah Randriamananjanahary	Employee	No	75,000	0.45	April 18, 2027	No
Anatole Pelletier	Employee	No	75,000	0.45	April 18, 2027	No
Brian Kai-Ming Cheng	Director	Yes	75,000	0.45	April 18, 2027	No
Bramhanand Ramjiawan	Director	Yes	75,000	0.45	April 18, 2027	No
Rashid Ahmed Maula Bux	CEO	Yes	850,000	0.45	April 18, 2027	No
Guoyu Huang	Interim CFO	Yes	400,000	0.45	April 18, 2027	No
		<b>TOTAL</b>	<b>4,625,000</b>			

Total Number of optioned shares proposed for acceptance: **4,625,000**

---

**FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT  
OR AMENDMENT**

## 2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares <sup>(1)</sup>	Exercise Price	Original Date of Grant	Expiry Date
	3,735,000	\$0.30	December 31, 2019	December 31, 2024
	2,410,000	\$0.40	July 14, 2022	July 14, 2025
	212,000	\$0.40	August 3, 2022	August 3, 2025
Total	6,357,000			

(1) Set out the number of optioned shares for each grant with different terms.

## 3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

**The option plan was approved by shareholders at Annual General Meeting on December 20, 2022.**

- (b) State the date of the news release announcing the grant of options.

**April 18, 2024**

- (c) State the total issued and outstanding share capital at the date of grant or amendment.

**As of the date of the grant, a total of 90,886,229 common shares of the Issuer are issued and outstanding.**

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options, and other presently outstanding options.

**The aggregate number of shares that are subject to incentive stock options, including new options, amended options, and other presently outstanding options represent 12.08% of the issued and outstanding shares of the Issuer.**

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

**2,650,934**

- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

**Not Applicable**

- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

**Not Applicable.**

#### 4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: April 18, 2024

Rashid Ahmed Maula Bux

Name of Director or Senior  
Officer

*"Rashid Ahmed Maula Bux"*

Signature

CEO

Official Capacity